• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHENG Lu, LIN Yunfei, DING Li, WEN Aidong, WU Yan, ZHANG Run. Pharmacokinetics of butoconazole nitrate suppositories in human[J]. Journal of China Pharmaceutical University, 2013, 44(6): 548-552. DOI: 10.11665/j.issn.1000-5048.20130612
Citation: CHENG Lu, LIN Yunfei, DING Li, WEN Aidong, WU Yan, ZHANG Run. Pharmacokinetics of butoconazole nitrate suppositories in human[J]. Journal of China Pharmaceutical University, 2013, 44(6): 548-552. DOI: 10.11665/j.issn.1000-5048.20130612

Pharmacokinetics of butoconazole nitrate suppositories in human

More Information
  • The aim of the study was to investigate the pharmacokinetics of butoconazole nitrate suppositories in healthy Chinese female volunteers after single and multiple-dose vaginal administration. 12 healthy Chinese female volunteers received single 0. 05 g, single 0. 1 g, multiple doses(0. 1 g per day, 3-day consecutive administration)and multiple doses(0. 1 g per day, 5-day consecutive administration)of butoconazole nitrate suppositories. For 0. 05 g and 0. 1 g single vaginal administration of butoconazole nitrate suppositories, the cmax were(0. 895 0±0. 261 0)and(1. 740±0. 511)ng/mL and the AUC0-96 h were(36. 38±10. 82)and(73. 48±28. 99)ng ·h/mL, respectively. In the range of 0. 05-0. 1 g, butoconazole demonstrated linear pharmacokinetics. In the multiple-dose study at 0. 1 g dose for 3 consecutive days, the degree of fluctuation(DF)was(0. 54±0. 27), and the accumulation parameters Rcmax and RAUC0-τ were(1. 3±0. 3)and(1. 4±0. 3), respectively. In the multiple-dose study at 0. 1 g dose for 5 consecutive days, the DF was(0. 64±0. 25), and the accumulation parameter Rcmax and RAUC were(1. 4±0. 3))and(1. 6±0. 2), respectively. An accumulation of 60% in AUC0-τ occurred after a multiple administration. The main pharmacokinetic parameters between 3-day consecutive administration and 5-day consecutive administration showed no significant difference.
  • [1]
    Jacobson JB,Hajman AJ,Wiese J,et al.A new vaginal antifungal agent-butoconazole nitrate[J].Acta Obstet Gyn Scan,1985,64(3):241-244.
    [2]
    Adamson GD, Brown D Jr, Standard JV, et al. Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis[J].J Reprod Med,1986,31(2):131-132.
    [3]
    Hajman AJ. Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream[J].J Int Med Res,1988,16(5):367-375.
    [4]
    Brown D,Henzl MR,Kaufman RH.Butoconazole nitrate 2% for vulvovaginal candidiasis.New,single-dose vaginal cream formulation vs.seven-day treatment with miconazole nitrate.Gynazole 1 study group[J].J Reprod Med,1999,44(11):933-993.
    [5]
    US FDA.Guidance for industry: bioanalytical method validation [EB/OL].USA,US Department of Health and Human Services,2001[2011-09-10].http: //www.fda.gov /downloads /Drugs /Guidance Compliance Regulatory Information /Guidances / UCM070107.pdf.
    [6]
    Chu Y,Ding L,Liu HY,et al.Determination of potassium oxonate in human plasma and urine and its pharmacokinetics and accumulation evaluation in human[J].J China Pharm Univ(中国药科大学学报),2011,42(5):436-442.
    [7]
    Droegemueller W,Adamson DG,Brown D,et al.Three-day treatment with butoconazole nitrate for vulvovaginal candidiasis[J].Obstet Gynecol,1984,64(4):530-534.
    [8]
    Tatum DM, Eggleston M. Butoconazole nitrate[J]. Infect Cont Hosp Ep,1988,9(3):122-124.
    [9]
    Wang Q,Chen GS.Progress in vaginal delivery systems[J].Chin J Mod Appl Pharm(中国现代应用药学),2005,22(1):34-36.
  • Related Articles

    [1]GUO Jiru, QIN Chunjun, HU Jing, CAO Xin, XU Yongxue, LIU Jiankai, YIN Jian. Quantitative determination of capsular polysaccharide, C-polysaccharide, phosphorus of carbohydrate antigens from Streptococcus pneumoniae by quantitative NMR using a single internal standard[J]. Journal of China Pharmaceutical University, 2024, 55(4): 472-477. DOI: 10.11665/j.issn.1000-5048.2024020502
    [2]YAO Jian, SHAO Lei, CHEN Daijie, ZHANG Yubin. Transcriptomic analysis of a spiramycin I-resistant Staphylococcus aureus mutant[J]. Journal of China Pharmaceutical University, 2017, 48(6): 738-744. DOI: 10.11665/j.issn.1000-5048.20170617
    [3]XING Ming-xun, JIA Sheng-mei, YUAN Peng, SHI Qi-yun, CHENG Wei, JIN Kun-qi, YU Lu. Inhibition of azithromycin on biofilms of Staphylococcus aureus[J]. Journal of China Pharmaceutical University, 2012, 43(6): 553-559.
    [4]Properties and Type Determinations of Exopenicillinases from Staphylococcus aureus[J]. Journal of China Pharmaceutical University, 1995, (3): 183-186.
    [5]Action of Cell-Bound Penicillinase in Mediating Resistance of Staphylococcus aureus[J]. Journal of China Pharmaceutical University, 1991, (6): 363-366.
    [6]Protoplast-Dependent Plasmid Elimination of Staphylococcus Aureus[J]. Journal of China Pharmaceutical University, 1990, (3): 179-181.
    [7]PLASMID ELIMINATION AND TRANSDUCTION OF STAPHYLOCOCCUS AUREUS RN1304 AND ITS ALBUS VARIANT[J]. Journal of China Pharmaceutical University, 1989, (3): 151-154.
    [8]PROPERTIES OF A BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS~*[J]. Journal of China Pharmaceutical University, 1988, (1): 38-41.
    [9]EXTRACTION AND DETECTION OF ANTIBIOTIC RESISTANT PLASMID DNA IN STAPHYLOCOCUS AUREUS[J]. Journal of China Pharmaceutical University, 1985, (2): 53-58.
    [10]ELIMINATION OF ANTIBIOTIC RESISTANT PLASMIDS IN STAPHYLOCOCCUS AUREUS[J]. Journal of China Pharmaceutical University, 1985, (2): 48-52.

Catalog

    Article views (1234) PDF downloads (1641) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return